MRB and IRB are bottlenecks, not safeguards - here's what's actually broken

The review boards exist for good reasons. The way most of them run, in 2026, isn't one of them.

Every Quality and Operations leader in Life Sciences has had the same week at some point. A non-conforming batch is on hold. A material is approaching expiry. A supplier deviation needs a disposition. The decision sits with the Material Review Board or the Inventory Review Board and three weeks later, it's still sitting there.

Nobody is doing anything wrong. The reviewers are diligent. The documentation is thorough. The approvals are appropriately rigorous. And yet the inventory is aging, the program is slipping, the customer is asking, and finance has already started modelling the reserve.

This isn't a quality problem. MRB and IRB are doing exactly what they were designed to do  apply cross-functional scrutiny to high-stakes inventory decisions. The mechanism is sound.

The operating model around it is what's broken.

That distinction matters, because it determines what you fix.

What MRB and IRB are actually for

A quick reset, because the terms get used loosely. The Material Review Board exists to disposition non-conforming material accept-as-is, rework, reject, return-to-supplier, scrap. The Inventory Review Board, in most organizations, handles the broader population: slow-movers, expiry-at-risk stock, obsolete materials, customer-cancelled WIP, change-driven orphan inventory.

Both boards exist because these decisions need quality, manufacturing, procurement, finance, and sometimes commercial in the same room. That cross-functional review is the safeguard. Removing it would be reckless.

The problem isn't that these decisions are reviewed. It's how the review actually runs.

Where the cycle time actually goes

When you decompose a typical MRB or IRB cycle in a pharma or CDMO setting, the review itself  the meeting where decisions get made  is rarely the bottleneck. It's everything around it.

Roughly: a non-conformance or expiry flag gets raised. Someone has to gather the context  the batch history, the deviation report, the supplier CoA, the customer contract terms, the affected lots downstream, the current finished-goods exposure. That packet gets emailed around for pre-review. Half the reviewers are out of office. The packet is incomplete and goes back for more information. By the time it reaches the formal meeting, the material has been sitting for two to four weeks. The meeting itself takes thirty minutes. The decision then needs documented approval, often from a director who's traveling. Reconciliation in the ERP happens days later. Finance picks it up the following month.

In a CDMO setting, multiply this by every customer program. In a pharma setting, multiply it by every site.

Now ask: where in that sequence is the quality of the decision being protected? The thirty-minute meeting. Everywhere else, time is leaking  and with perishable materials, time leaking is value leaking.

The three failures that actually slow MRB/IRB down

When you look at hundreds of these cycles across pharma and perishable-goods companies, the same three structural failures show up almost every time.

1. No clear liability owner at the moment the flag is raised. Is this customer-owned material? Is the supplier on the hook? Did a forecast change clause get triggered? Is this internal waste? Each path has a different reviewer set, a different documentation requirement, and a different financial owner. In most companies, that determination happens during the review instead of before it. The board spends its first meeting figuring out who should have been in the room.

2. Context is assembled manually, every time, from scratch. The data exists. The batch record exists, the contract exists, the inventory aging report exists, the change history exists. They live in five different systems and a SharePoint folder. A planner or a quality associate spends days stitching them together for each case  and then someone else does it again next month for the next case, on the same SKU, often with the same suppliers.

3. The workflow is email. Approvals chase people who are traveling. Versions drift. Decisions get made verbally in a meeting and then have to be re-documented to be auditable. Reconciliation back into the ERP  the actual scrap, the reserve adjustment, the chargeback  happens days or weeks after the decision, and sometimes doesn't happen at all.

None of these are quality failures. All of them are operating-model failures wearing a quality costume.

What "digital MRB/IRB" actually means

It does not mean replacing the review board. It means giving the review board a system that does the work the review board shouldn't have been doing in the first place.

Concretely: the moment a non-conformance, expiry signal, or change event creates a candidate for review, the case opens itself  with the full context package already assembled. Batch history, contract terms, affected downstream inventory, current liability assessment, recommended dispositions with rationale, financial impact preview. Reviewers get the right cases routed to them based on the type of disposition, not a blanket distribution list. Approvals happen in-system with full audit trail. The ERP write-back and the financial reserve update happen automatically when the decision closes.

The board still decides. The board just stops being a clearinghouse for missing information.

In a typical pharma site, this is the difference between a three-week MRB cycle and a three-day one. For a CDMO managing customer-owned materials across programs, it's the difference between recovering chargebacks in the same quarter the liability event occurred and absorbing them silently into next year's margin.

The honest reframe

When ops and quality leaders talk about MRB or IRB being "slow," what they're usually describing isn't slow deliberation  it's slow coordination. The decision itself, when made, is sound. Everything around the decision is structurally inefficient in ways that have nothing to do with whether the safeguard is working.

This is the layer Traceflow is built for: digital MRB and IRB workflows, automatic liability assessment, context assembled at the moment of flag, routing tied to the type of disposition, reconciliation back into the ERP without manual rework. The board keeps its job. It just gets its weeks back.

The safeguard isn't the problem. The choreography around it is. Fix that, and the MRB stops being a place where inventory goes to age.